Clinical Trials Logo

Metastases clinical trials

View clinical trials related to Metastases.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02414269 Active, not recruiting - Breast Cancer Clinical Trials

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Start date: May 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this Phase I study is to test the safety of different doses of specially prepared immune cells (called "T cells") collected from blood. The Investigators want to find a safe dose of these modified T cells for patients who have malignant pleural disease. They want to find out what effects these T cells have on the patient and the cancer (MPD). Phase 2 part of the study, the investigators will test the dose in combination with another drug, pembrolizumab, to see what effects the study treatment has on malignant pleural mesothelioma.

NCT ID: NCT02301858 Active, not recruiting - Lung Cancer Clinical Trials

Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases

Start date: December 2013
Phase: N/A
Study type: Interventional

The project aims to compare the histopathological and molecular characteristics of tumour tissue from metastases with similar analyses of the primary tumour in the lung, where it is available. The investigators will therefore perform analysis of blood samples if possible, to identify predictive markers in blood samples.

NCT ID: NCT01442246 Active, not recruiting - Metastases Clinical Trials

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

Start date: July 2011
Phase: Phase 3
Study type: Interventional

PRINCIPAL OBJECTIVE: Evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence. SECONDARY OBJECTIVE(S): - PSA evolution - Evaluation of testosterone level - Specific survival - Overall survival - Tolerance - Quality of life (QLQ-C30 questionnaires)